with the


To find new therapeutic solutions that help us combat infections caused by  resistant bacteria by using fungi as a natural source of pharmaceuticals, contributing to the challenge “ One Health” established by the WHO.


Our vision is to revolutionize the field of healthcare by harnessing the power of fungi as a natural source of pharmaceuticals. We are discovering and developing innovative therapeutic solutions to combat antibiotic-resistant infections and address major infectious threats. Our ultimate goal is to improve human health and well-being by unlocking the potential of fungi and advancing the frontiers of medical science.


Our core values

Our early drug discovery pipeline is powered by a one-of-a-kind platform, the Activotheque.

This platform is connected with the largest private Mycotheque in Europe, Hifas Biologics' organized repository of fungal strain samples.


The mycotheque boasts a vast and diverse repository of fungal strain samples.

It is the largest private mycotheque in Europe, ensuring confidentiality and exclusivity of the samples.

The samples in the mycotheque consist of metabolites, peptides, and proteins, providing a rich source of bioactive compounds.

Therapeutic validation of the extracts' properties is conducted through functional assays and fractionation to identify their antibiotic properties.

Fractions with higher pharmacological value are integrated into the Activotheque, ensuring that the most promising compounds are available for study and development.

The mycotheque is continuously expanding, guaranteeing a growing number of strains available.

Innovative cultivation and extraction processes have been developed specifically for these fungal strains, allowing the acquisition of new chemical entities and therapeutically relevant compounds.

The mycotheque provides a valuable tool for research in the field of antibiotic resistance and the search for new treatments against infectious threats.

Our Activotheque is an exclusive platform for early fungi-sourced-drugs discovery enriched by fractions from our private Mycotheque, ensuring that our fractions:

  • have antimicrobial activity
  • great potential in addressing pharmaceutical developments

This development methodology is a continuous, agile, and effective process that will continue to enrich and functionally characterize our own mycological collection, allowing us to discover new antibiotics from fungi.

The creation of a solid and consistent portfolio of patents around the most relevant fractions will ensure the intellectual protection of the results.

Innovative antibiotics results

At Hifas Biologics, we have already evaluated:


tests against antibiotic activity, 17 for bacteria and 3 for fungi, all listed in the WHO Global Priority Pathogens List.


samples from our Mycotheque


samples has shown activity against 10 pathogens (31 %)

Project Portfolio

Pathogens targeted

Project Category: Pathogens


Streptococcus pneumoniae

Pneumococcal pneumonia hospitalizes about 150,000 people in the United States each year, with a mortality rate of approximately 5-7 percent, or 1 in every 20 infected individuals.
Read more
Project Category: Pathogens


Streptococcus agalactiae

Streptococcus agalactiae is responsible for nearly 100,000 deaths in newborns, at least 46,000 prenatal deaths, It is  associated with over half a million premature births each year.
Read more
Project Category: Pathogens


Neisseria gonorrhoeae

Neisseria gonorrhoeae causes gonorrhea, WHO has estimated that 82.4 million new cases were reported in 2020 and 550k drug-resistant Neisseria gonorrhoeae infections only in the US.
Read more
Project Category: Pathogens


Campylobacter jejuni

Campylobacter jejuni causes intestinal infections that affect 1.5 million infections and $270 million in direct medical costs each year.
Read more
Project Category: Pathogens


Cryptococcus neoformans

Cryptococcosis caused by C. neoformans is a very serious disease, with a mortality rate ranging from 41% to 61%, particularly in patients with HIV infection.
Read more

Be part of the company
Fleming would’ve invested in